StockData
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC) stock

FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.71−0.06 (-1.59%)

Close on Nov 16, 2026Market cap $283.06MP/E –Yield –

Fulcrum Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Fulcrum Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $44.98M, down 14.2% year over year. For fiscal 2025 it was $56.10M, down 11.5% from the year before. The highest annual figure on record is $76.78M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$56.10M-11.5%
FY2024Dec 31, 2024$63.39M-11.7%
FY2023Dec 31, 2023$71.80M-6.5%
FY2022Dec 31, 2022$76.78M+10.2%
FY2021Dec 31, 2021$69.70M+18.1%
FY2020Dec 31, 2020$59.04M-16.9%
FY2019Dec 31, 2019$71.07M+182.2%
FY2018Dec 31, 2018$25.18M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$3.03M-78.8%
Q2 FY2026Jun 30, 2026$12.44M-4.2%
Q1 FY2026Mar 31, 2026$14.08M+5.1%
Q4 FY2025Dec 31, 2025$15.42M+31.6%
Q3 FY2025Sep 30, 2025$14.30M-2.3%
Q2 FY2025Jun 30, 2025$12.99M-24.8%
Q1 FY2025Mar 31, 2025$13.40M-32.2%
Q4 FY2024Dec 31, 2024$11.71M-38.3%
Q3 FY2024Sep 30, 2024$14.64M-19.7%
Q2 FY2024Jun 30, 2024$17.26M-3.3%
Q1 FY2024Mar 31, 2024$19.77M+18.3%
Q4 FY2023Dec 31, 2023$19.00M+2.3%
Q3 FY2023Sep 30, 2023$18.24M+18.7%
Q2 FY2023Jun 30, 2023$17.85M-28.7%
Q1 FY2023Mar 31, 2023$16.72M-6.3%
Q4 FY2022Dec 31, 2022$18.57M-1.8%
Q3 FY2022Sep 30, 2022$15.37M-10.0%
Q2 FY2022Jun 30, 2022$25.02M+44.0%
Q1 FY2022Mar 31, 2022$17.83M+9.2%
Q4 FY2021Dec 31, 2021$18.91M+17.1%
Q3 FY2021Sep 30, 2021$17.08M+9.2%
Q2 FY2021Jun 30, 2021$17.38M+36.0%
Q1 FY2021Mar 31, 2021$16.33M+12.8%
Q4 FY2020Dec 31, 2020$16.15M+33.6%
Q3 FY2020Sep 30, 2020$15.64M+15.9%
Q2 FY2020Jun 30, 2020$12.78M+17.6%
Q1 FY2020Mar 31, 2020$14.48M-58.2%
Q4 FY2019Dec 31, 2019$12.09M+76.2%
Q3 FY2019Sep 30, 2019$13.50M+93.8%
Q2 FY2019Jun 30, 2019$10.86M+87.6%
Q1 FY2019Mar 31, 2019$34.63M–
Q4 FY2018Dec 31, 2018$6.86M–
Q3 FY2018Sep 30, 2018$6.96M–
Q2 FY2018Jun 30, 2018$5.79M–

More Fulcrum Therapeutics figures

See a number that looks wrong?